Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 06:58 ET | Source: Felix Health Inc.

Felix Offers Ozempic at Generic-Level Pricing as Lower-Cost GLP-1 Demand Remains Elevated Across Canada

Felix expands lower-cost GLP-1 access, offering Ozempic at generic-level pricing with free-start program and ongoing clinical support
May 26, 2026 11:30 ET | Source: SNS Insider pvt ltd

GLP-1 Receptor Agonist Market Projected to Reach USD 307 Billion by 2035 Driven by Expanding Metabolic Disease Burden – SNS Insider

Austin, United States, May 26, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, the global GLP-1 Receptor Agonist Market was valued at USD 60.6 Billion in 2025 and is expected to reach USD 307...
May 19, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
May 13, 2026 02:00 ET | Source: Novo Nordisk A/S

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026

Wegovy® pill showed 21.6% weight loss in early responders and improved mobility in OASIS-4 data at ECO2026.
May 12, 2026 07:00 ET | Source: Felix Health Inc.

Felix Health to Lower Semaglutide Pricing by Up to 65% as Lower-Cost Options Enter Canada

Felix to lower semaglutide pricing by up to 65% as generic options enter Canada, helping improve affordability for weight management patients.
May 12, 2026 06:25 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

Novo Nordisk today announced data demonstrating that Wegovy® delivers substantial and consistent weight-loss results for women.
May 12, 2026 04:00 ET | Source: AKAMPION

EktaH Shows ~50% Reduction in Post-GLP-1 Weight Rebound with Novel Obesity Treatment and Reports Positive Phase I Data

Novel alternative to GLP-1 drugs: Phase I data demonstrate fat mass reduction, preservation of lean mass, 80% responder rate, and no serious adverse events
April 28, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey.
April 13, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting
March 19, 2026 11:40 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.